Psychedelics Research

Podcast - Intro To A Toll-Free Psychedelics Information Line, An Educational Tool By Unlimited Sciences
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute

Psychedelics Research Recent News

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Congress Discusses Remaining FY2024 Spending Bill With Provisions On Cannabis Sales And Psychedelic Clinical Trials
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Red Light Holland Exports Psilocybin For Research, Microdosing Capsules And More News From This Canadian Company
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development.
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. 
DEA Acknowledges Psychedelics & Cannabis Research Needs, Seeks Production Increases
The Drug Enforcement Administration (DEA) has proposed a considerable surplus to the originally-established 2023 production quotas of cannabinoids and psychedelics toward supporting preclinical and clinical research.
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.
Harvard's New Psychedelics Research Program Backed By Former Tesla Director's $16M Donation
Harvard University will create a Study of Psychedelics in Society and Culture backed by a $16 million gift from a former Tesla (NASDAQ: TSLA) employee, recalling 
Esteemed Psychedelic Researcher And Pioneer Roland Griffiths Passes Away At Age 77
A sad day in the psychedelics community today as news filters out that leading industry neuroscientist, Dr. Roland Griffiths, Ph.D., has passed.